There are currently 997 clinical trials in Portland, Oregon looking for participants to engage in research studies. Trials are conducted at various facilities, including Oregon Health & Science University, Oregon Health and Science University /ID# 216891, Providence Portland Medical Center and Providence Saint Vincent Medical Center. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Phase 3 Study of Toripalimab Alone or in Combination With Tifcemalimab as Consolidation Therapy in Patients With Limited-stage Small Cell Lung Cancer (LS-SCLC)
NCT06095583
Recruiting
The Study is a Phase 3, randomized, three-arm, double-blind, placebo-controlled, multi-regional clinical research study to evaluate the safety and efficacy use of toripalimab alone or in combination with tifcemalimab as consolidation therapy in patients with limited-stage small cell lung cancer without disease progression following chemoradiotherapy. Tifcemalimab is a monoclonal antibody against B and T lymphocyte attenuator (BTLA). Toripalimab is a monoclonal antibody against programmed death... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/19/2024
Locations: Oregon Health and Science University, Portland, Oregon
Conditions: Limited-stage Small Cell Lung Cancer (LS-SCLC)
Register for Updates
Phase Ib Trial of Multivalent Autophagosome Vaccine With or Without GITR Agonist, With Anti-PD-1 Immunotherapy in HNSCC
NCT04470024
Recruiting
This is a phase Ib study with a safety lead-in (n = 6 per arm) evaluating combinatorial DPV-001 + sequenced PD-1 blockade, with or without GITR agonist, in recurrent or metastatic HNSCC.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/18/2024
Locations: Portland Providence Medical Center, Portland, Oregon
Conditions: Cancer of the Head and Neck
Register for Updates
A Study of TSR-022 in Participants With Advanced Solid Tumors (AMBER)
NCT02817633
Recruiting
This is a first-in-human study evaluating the anti-T cell immunoglobulin and mucin containing protein-3 (TIM-3) antibody TSR-022. The study will be conducted in 2 parts with Part 1 consisting of dose escalation and Part 2 dose expansion. Part 1 will determine the recommended Phase 2 dose (RP2D) of TSR-022 and Part 2 will evaluate the antitumor activity of TSR-022 in combination with TSR-042 or docetaxel and as monotherapy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/18/2024
Locations: GSK Investigational Site, Portland, Oregon
Conditions: Neoplasms
Register for Updates
Reducing Intraoperative ESKAPE Transmission Through Use of a Personal Hand Hygiene System
NCT04900298
Recruiting
The investigators hypothesize that the use of a personal hand hygiene system (SafeHavenTM) by anesthesia providers in the adult operating room, combined with a novel infectious pathogen tracking system (OR PathTrac) will decrease participant exposure to pathologic bacteria in the adult operating room.
Gender:
ALL
Ages:
Between 18 years and 99 years
Trial Updated:
06/18/2024
Locations: Oregon Health and Science University, Portland, Oregon
Conditions: Surgical Wound Infection, Cross Infection
Register for Updates
EXHIT ENTRE Implementation Trial of High Intensity Versus Low Intensity Strategy
NCT04921787
Recruiting
This study is a multi-site, cluster randomized, two group implementation trial comparing a low- versus high-intensity implementation strategy for supporting hospital-based opioid use disorder treatment (HBOT) in community hospital settings where medication for opioid use disorder (MOUD) treatment has not been implemented.
Gender:
ALL
Ages:
All
Trial Updated:
06/14/2024
Locations: Oregon Health & Science University, Portland, Oregon
Conditions: Substance Use Disorders, Opioid Use Disorder, Severe, Opioid Use Disorder, Moderate
Register for Updates
Pragmatic Evaluation of Events And Benefits of Lipid-lowering in Older Adults
NCT04262206
Recruiting
PREVENTABLE is a multi-center, randomized, parallel group, placebo-controlled superiority study. Participants will be randomized 1:1 to atorvastatin 40 mg or placebo. This large study conducted in community-dwelling older adults without cardiovascular disease (CVD) or dementia will demonstrate the benefit of statins for reducing the primary composite of death, dementia, and persistent disability and secondary composites including mild cognitive impairment (MCI) and cardiovascular events.
Gender:
ALL
Ages:
75 years and above
Trial Updated:
06/14/2024
Locations: Oregon Health and Science University, Portland, Oregon
Conditions: Cognitive Impairment, Mild, Dementia, Cardiovascular Diseases
Register for Updates
Roflumilast or Azithromycin to Prevent COPD Exacerbations (RELIANCE)
NCT04069312
Recruiting
A multi-center, randomized, 72-month, parallel- group, non-inferiority, phase III study to compare the effectiveness of roflumilast (Daliresp, 500 mcg quaque die (QD) or alternate regimen) therapy versus azithromycin (250 mg QD, 500 mg QD three times per week, or alternate regimen) to prevent hospitalization or death in a patients at high risk for COPD exacerbations.
Gender:
ALL
Ages:
40 years and above
Trial Updated:
06/06/2024
Locations: Kaiser Permanente, Portland, Oregon
Conditions: Chronic Obstructive Pulmonary Disease Severe, Chronic Bronchitis
Register for Updates
Mitral Valve Screening Survey
NCT04736667
Recruiting
This study aims to examine the clinical profile/anatomical characteristics and natural history of patients who subsequently fail screening for transcatheter mitral valve intervention (TMVI).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/03/2024
Locations: Oregon Health Sciences University, Portland, Oregon
Conditions: Mitral Valve Disease
Register for Updates
Parkinson's Foundation PD GENEration Genetic Registry
NCT04994015
Recruiting
Development of a central repository for PD-related genomic data for future research.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/28/2024
Locations: Oregon Health and Science University, Portland, Oregon
Conditions: Parkinson's Disease
Register for Updates
HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide
NCT04904588
Recruiting
This is a prospective, multi-center, Phase II study of hematopoietic cell transplantation (HCT) using human leukocyte antigen (HLA)-mismatched unrelated donors (MMUD) for peripheral blood stem cell transplant in adults and bone marrow stem cell transplant in children. Post-transplant cyclophosphamide (PTCy), tacrolimus and mycophenolate mofetil (MMF) will be used for for graft versus host disease (GVHD) prophylaxis. This trial will study how well this treatment works in patients with hematologic... Read More
Gender:
ALL
Ages:
1 year and above
Trial Updated:
05/22/2024
Locations: Oregon Health and Science University, Portland, Oregon
Conditions: Acute Lymphoblastic Leukemia, Acute Myelogenous Leukemia, Mixed Phenotype Acute Leukemia, Acute Leukemia, Myelodysplastic Syndromes, Chronic Myelogenous Leukemia, Chronic Lymphocytic Leukemia, Lymphoma
Register for Updates
Descartes-08 CAR-T Cells in Generalized Myasthenia Gravis (MG)
NCT04146051
Recruiting
This is a Phase IIb study to evaluate the safety and preliminary efficacy of Descartes-08 CAR T-cells in patients with Generalized Myasthenia Gravis
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/22/2024
Locations: Oregon Health & Science University, Portland, Oregon
Conditions: Myasthenia Gravis, Generalized
Register for Updates
HF2 Registry - Hemodynamic Frontiers in Heart Failure Registry
NCT06425848
Recruiting
The purpose of the HF2 (Hemodynamic Frontiers in Heart Failure) registry is to collect relevant patient-level demographic, clinical, laboratory, and hemodynamic data from patients implanted with pulmonary artery pressure sensor at participating centers to advance scientific knowledge about ambulatory hemodynamics monitoring and HF (Heart Failure) therapies. The data collected will be used for retrospective studies, quality improvement, identifying research cohorts, and member-initiated research.
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
05/21/2024
Locations: Providence Heart Institute, Portland, Oregon
Conditions: Heart Failure
Register for Updates